Melbourne, Australia – In a significant stride towards addressing a critical challenge in lung cancer treatment, Racura Oncology has initiated the HARNESS-1 trial, marking the first patient treated with its novel compound, RC220, in combination with the established therapy osimertinib. This groundbreaking Phase Ia/b clinical trial aims to tackle the pervasive issue of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant non-small cell lung cancer (NSCLC). The first participant received the investigational drug at Monash Health in Clayton, Victoria, signaling the commencement of a multi-centre study with further sites poised to open imminently.
The HARNESS-1 trial represents a beacon of hope for a patient population often left with limited therapeutic options once resistance to current standard-of-care treatments emerges. EGFR-mutant NSCLC, a molecularly defined subtype of lung cancer, has seen remarkable progress with the advent of targeted therapies like osimertinib. However, the inevitable development of resistance to these drugs underscores the urgent need for innovative strategies that can either prevent or overcome this hurdle, thereby extending patient survival and improving quality of life.
The Challenge of TKI Resistance in EGFR-Mutant NSCLC
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 85% of all cases. Within this broad category, a significant subset of patients harbor specific genetic mutations in the EGFR gene. These mutations render the cancer cells dependent on the EGFR pathway for growth and survival, making them particularly susceptible to therapies designed to inhibit this pathway. Osimertinib, a third-generation EGFR TKI, has revolutionized the treatment landscape for EGFR-mutant NSCLC, demonstrating superior efficacy and improved tolerability compared to earlier generations of TKIs.
However, the success of osimertinib, like other targeted therapies, is often temporary. Over time, cancer cells can evolve and develop mechanisms of resistance, rendering the drug ineffective. This acquired resistance is a major clinical challenge, often leading to disease progression and necessitating a switch to alternative, and sometimes less effective, treatment regimens. Understanding the molecular underpinnings of this resistance is paramount to developing effective counter-strategies.
The mechanisms driving acquired resistance to EGFR TKIs are diverse and complex. They can include:
- Secondary EGFR Mutations: The most common mechanism involves the emergence of new mutations in the EGFR gene, such as the T790M mutation, which was historically targeted by osimertinib, or other less common mutations that alter the drug’s binding site.
- Bypass Receptor Activation: Cancer cells can activate alternative signaling pathways that promote growth and survival, effectively bypassing the inhibited EGFR pathway. This can involve the activation of other receptor tyrosine kinases, such as MET or HER2.
- Reactivation of Downstream Signaling Pathways: Even if EGFR is inhibited, downstream signaling molecules within the cell can become abnormally activated, leading to continued proliferation and survival.
- Tumor Adaptation and Phenotypic Switching: Cancer cells can undergo significant changes in their cellular characteristics, such as transforming into small cell lung cancer (SCLC), which is inherently resistant to EGFR TKIs.
The HARNESS-1 trial is specifically designed to address this critical unmet need by exploring a novel approach to combat these resistance mechanisms.
Introducing RC220: A Novel Mechanism of Action
At the heart of the HARNESS-1 trial is RC220, an investigational compound developed by Racura Oncology. RC220 is a proprietary formulation of (E,E)-bisantrene, a compound with a unique mechanism of action that differentiates it from traditional chemotherapy and targeted therapies. Unlike conventional drugs that primarily target DNA replication or specific cellular processes, RC220 is designed to interact with and disrupt non-canonical G-quadruplex deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) structures.
G-quadruplexes are highly stable, four-stranded secondary structures that can form in G-rich regions of DNA and RNA. These structures are increasingly recognized as crucial regulators of gene expression, particularly in cancer. By targeting these structures, RC220 aims to interfere with critical cellular processes that drive cancer proliferation and survival. Specifically, it is believed to disrupt key oncogenic pathways, including the regulation of cellular myelocytomatosis oncogene (c-MYC), a potent oncogene that plays a central role in cell growth, proliferation, and survival. By targeting G-quadruplexes, RC220 has the potential to exert a broad anti-cancer effect by inhibiting the expression and function of genes essential for tumor growth.
The combination of RC220 with osimertinib in the HARNESS-1 trial is based on a compelling scientific rationale. The hypothesis is that while osimertinib effectively targets the primary EGFR mutations, RC220’s distinct mechanism of action may prevent or delay the emergence of resistance mechanisms by targeting fundamental regulatory elements within cancer cells. This dual approach aims to create a more robust and durable response, potentially extending the period of disease control for patients.
The HARNESS-1 Trial: A Phased Approach to Evaluation
The HARNESS-1 trial is a multi-centre study meticulously designed to comprehensively assess the safety, tolerability, and preliminary efficacy of RC220 in combination with osimertinib. The trial is structured in distinct phases, allowing for a systematic and rigorous evaluation of the investigational therapy.
Phase Ia: Dose Escalation
The initial phase of the trial, Phase Ia, focuses on dose escalation. This stage involves treating small cohorts of patients with progressively increasing doses of RC220, while maintaining a standard dose of osimertinib. The primary objective of this phase is to determine the maximum tolerated dose (MTD) of RC220 when administered in combination with osimertinib. Safety and tolerability are closely monitored, with a particular focus on identifying any adverse events that may arise from the combination therapy. This dose-escalation phase will initially involve single-patient cohorts at increasing doses, with the aim of progressing to establish the MTD for broader evaluation in up to 40 patients.
Phase Ib: Expansion and Molecular Assessment
Following the identification of the MTD, the trial will transition to a Phase Ib expansion stage. This phase is designed to further evaluate the safety and tolerability of the combination therapy at the determined MTD. More importantly, it will focus on assessing the pharmacokinetics (how the body absorbs, distributes, metabolizes, and excretes the drugs) and early clinical activity of the combination. This includes monitoring for molecular responses, such as changes in tumor markers, and evaluating preliminary survival outcomes.
A key innovative feature of the HARNESS-1 trial is the inclusion of an observational screening stage that utilizes circulating tumor DNA (ctDNA) analysis. ctDNA, which are fragments of DNA shed by tumors into the bloodstream, can provide valuable insights into the genetic landscape of a patient’s cancer. This screening process will help confirm patient eligibility and potentially identify biomarkers that could predict response to the combination therapy.
The Phase Ib expansion stage will be double-blind and randomized, a critical design element that minimizes bias and enhances the reliability of the results. This means that neither the patients nor the researchers will know which treatment the patient is receiving (though all patients will receive the combination of RC220 and osimertinib, the specific dosing and potentially other factors might be blinded in certain comparisons or assessments). This design allows for a robust assessment of the treatment’s impact.
The First Patient and the Path Forward
The treatment of the first patient at Monash Health marks a significant operational milestone for Racura Oncology and the HARNESS-1 trial. The initial administration of RC220 at a dose of 50mg/m² intravenously was reportedly well-tolerated, with the patient not reporting any adverse events. This early indication of safety is encouraging, though it is important to note that this is a single data point in the early stages of a comprehensive trial.
"Dosing the first patient in HARNESS-1 is an important milestone for Racura and for the clinical development of RC220," said Daniel Tillett, CEO of Racura Oncology. "The scientific rationale for this trial is grounded in the urgent need to address TKI therapeutic resistance in EGFR-mutant NSCLC. We are optimistic that this novel combination therapy holds the potential to significantly improve outcomes for patients facing this challenging disease."
The selection of Monash Health in Clayton, Victoria, as the inaugural trial site underscores Australia’s growing role in global clinical research and its commitment to advancing cancer therapies. The establishment of additional trial sites in the near future will be crucial for recruiting a diverse patient population and accelerating the trial’s progress. This expansion will allow for broader geographical access to the investigational treatment and will facilitate the collection of robust data across multiple clinical settings.
Implications and Future Outlook
The HARNESS-1 trial holds significant implications for the future of lung cancer treatment. If successful, the combination of RC220 and osimertinib could offer a new paradigm for managing EGFR-mutant NSCLC, particularly in patients who develop or are at risk of developing resistance to current therapies. The potential to delay or prevent resistance could translate into longer periods of disease control, improved survival rates, and a better quality of life for a substantial number of patients.
The trial’s focus on targeting G-quadruplex structures represents a novel approach that could open new avenues for drug development not only in lung cancer but potentially in other oncological indications where these structures play a critical role. The use of ctDNA analysis as a screening tool also highlights the increasing integration of precision medicine techniques in clinical trials, enabling more personalized and effective treatment strategies.
The journey from initial patient dosing to regulatory approval is a long and complex one, requiring rigorous scientific validation and adherence to stringent regulatory standards. However, the initiation of the HARNESS-1 trial signifies a critical step forward. Racura Oncology’s commitment to addressing a significant unmet medical need, coupled with the innovative scientific approach of RC220, offers a promising outlook for patients battling EGFR-mutant NSCLC and underscores the ongoing advancements in the fight against cancer. The global medical community will be keenly watching the progress of the HARNESS-1 trial as it unfolds.
About the Author
